Treatment of Chronic Hepatitis D with Bulevirtide-A Fight against Two Foes-An Update.
Peter FerenciThomas ReibergerMathias JachsPublished in: Cells (2022)
HDV infection frequently causes progression to cirrhosis and hepatocellular carcinoma (HCC). In summer 2020, the first potentially effective drug Bulevirtide (BLV) has been approved for the treatment of HDV by the EMA. BLV is a synthetic N-acylated pre-S1 lipopeptide that blocks the binding of HBsAg-enveloped particles to the sodium taurocholate co-transporting polypeptide (NTCP), which is the cell entry receptor for both HBV and HDV. In this review, we discuss the available data from the ongoing clinical trials and from "real world series". Clinical trials and real-world experiences demonstrated that BLV 2 mg administered for 24 or 48 weeks as monotherapy or combined with pegIFNα reduces HDV viremia and normalizes ALT levels in a large proportion of patients. The combination of BLV and pegIFNα shows a synergistic on-treatment effect compared with either one of the monotherapies.
Keyphrases
- clinical trial
- hepatitis b virus
- end stage renal disease
- mental health
- chronic kidney disease
- newly diagnosed
- stem cells
- ejection fraction
- single cell
- machine learning
- drug delivery
- mesenchymal stem cells
- transcription factor
- open label
- cell therapy
- patient reported outcomes
- peritoneal dialysis
- liver failure
- replacement therapy